Aberrant Transcriptional Signalling In The Progression And Metastasis Of Melanoma.
Funder
National Health and Medical Research Council
Funding Amount
$353,033.00
Summary
There are currently no treatments that have any impact on decreasing mortality from metastatic melanoma. We have found 2 new variants in melanoma that may control the tumour growing and invading around the body. This study will examine the protein containing these changes with the aims of finding how they function differently, to identify their roles in the formation of melanoma, as well as to identify new targets for prevention and treatment of metastatic disease.
Deciphering Mechanisms Of Disease Evolution In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$845,093.00
Summary
In many patients, cancers are ever-changing, even after they have formed. This explains why many cancers can spread beyond the point of cure by surgery and why they can become resistant to treatments. This project will use patient melanomas and laboratory modelling to understand how melanomas change as they grow and spread. The results will be used to identify the nature of evolutionary changes in cancer in order to predict and even exploit them in treatment.
Effects Of A Novel Hotspot Mutation Of Brm In Non-Melanoma Skin Cancer Development
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
Australia has the highest incidence of skin cancer in the world. SWI/SNF, a yeast nucleosome remodeling complex, is known destabilise interactions in DNA. It is made up of 8-10 proteins, including a novel tumour suppressor Brm. There is some evidence that Brm acts as a tumour suppressor in skin cancer, but relevance of a recently found mutation in Brm is yet to be characterised. This project aims to identify the effect of this mutation, on cellular sensitivity to UV radiation and examine transfo ....Australia has the highest incidence of skin cancer in the world. SWI/SNF, a yeast nucleosome remodeling complex, is known destabilise interactions in DNA. It is made up of 8-10 proteins, including a novel tumour suppressor Brm. There is some evidence that Brm acts as a tumour suppressor in skin cancer, but relevance of a recently found mutation in Brm is yet to be characterised. This project aims to identify the effect of this mutation, on cellular sensitivity to UV radiation and examine transformation to malignancy.Read moreRead less
Early Detection Of Melanoma Metastases Using MicroRNA As Novel Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$109,363.00
Summary
The use of a minimally invasive blood test to measure the circulating levels of melanoma-specific miRNAs may provide a rapid assessment for clinical management of the disease during dissemination of the tumour. This work has the potential to provide new prognostic markers for melanoma as well as to identify new gene targets for the design of rational therapies to treat this disease.
A Lineage Specific Pathway For Progression Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$485,746.00
Summary
Melanoma is an insidious cancer, and its incidence has increased dramatically over the past four decades. Melanoma has an almost universally poor prognosis once metastasis has occurred. There are currently no treatment regimens that have a significant impact on prolonging survival or decreasing mortality from metastatic melanoma. Our preliminary data has shown the importance of a factor found in normal melanocytes in control over expression of a separate factor required for invasion and metastas ....Melanoma is an insidious cancer, and its incidence has increased dramatically over the past four decades. Melanoma has an almost universally poor prognosis once metastasis has occurred. There are currently no treatment regimens that have a significant impact on prolonging survival or decreasing mortality from metastatic melanoma. Our preliminary data has shown the importance of a factor found in normal melanocytes in control over expression of a separate factor required for invasion and metastasis of melanoma. These markers could serve as an important diagnostic marker for melanoma. Further, they may be suitable drug targets for the prevention and treatment of metastatic melanoma, and will advance our understanding of how melanoma spreads.Read moreRead less
Determining The Natural History Of Localized High-risk Melanoma And Risk Factors For Melanoma Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$103,980.00
Summary
This PhD thesis aims to describe 2-year survival rates of patients with localised melanoma. We will investigate risk factors and patterns of melanoma spread in patients with high-risk localised lesions. Risk factors for developing ulcerated versus non-ulcerated melanomas will be explored. We aim to describe support service use in melanoma patients in rural, regional and urban areas in Queensland.
A Randomised Phase III Study Of The Duration Of The Anti-PD1 - Therapy In Metastatic Melanoma (STOP-GAP)
Funder
National Health and Medical Research Council
Funding Amount
$2,308,600.00
Summary
PD-1 inhibitors turn on the immune system,so that it can fight the cancer cells in the body and are effective in Melanoma. This study investigates whether interrupted PD-1 inhibitor dosing has no worse Melanoma outcome than continuous treatment for 24 months, which may lead to a reduction in treatment-related toxicities, improvements in patients' quality of life and decrease the cost of treatment to the health system as well as individual. Results may inform treatments for other common cancers.